(Q33737975)

29 July 2017

title

In vitro activity of HR 810, a new cephalosporin (English)

1 reference

29 July 2017

M A Bertram

1

1 reference

29 July 2017

D A Bruckner

series ordinal

2

1 reference

29 July 2017

L S Young

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 August 1984

1 reference

Antimicrobial Agents and Chemotherapy

29 July 2017

published in

1 reference

29 July 2017

volume

26

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

277-279

1 reference

The new beta-lactamase-stable cephalosporins

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Prolonged Bleeding Times and Bleeding Diathesis Associated With Moxalactam Administration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

In vitro activity of HR 810, a new broad-spectrum cephalosporin

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=284139

Coagulopathy associated with the use of moxalactam

30 October 2018

1 reference

12 December 2020

Relation between beta-lactamase production and antimicrobial activity: Comparison of the new compound HR 810 with cefotaxime

1 reference

12 December 2020

HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase

1 reference

12 December 2020

HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum

1 reference

12 December 2020

The antibacterial activity in vitro and β-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.26.2.277

1 reference

29 July 2017

1 reference

29 July 2017

1 reference